Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Sold by Schonfeld Strategic Advisors LLC

Schonfeld Strategic Advisors LLC decreased its stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 83.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 64,850 shares of the biotechnology company's stock after selling 330,597 shares during the period. Schonfeld Strategic Advisors LLC's holdings in Iovance Biotherapeutics were worth $480,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Northern Trust Corp lifted its stake in Iovance Biotherapeutics by 7.4% in the fourth quarter. Northern Trust Corp now owns 2,414,807 shares of the biotechnology company's stock valued at $17,870,000 after buying an additional 166,231 shares during the last quarter. Quarry LP acquired a new position in Iovance Biotherapeutics during the 4th quarter valued at about $74,000. Virtus ETF Advisers LLC boosted its stake in Iovance Biotherapeutics by 12.4% during the 4th quarter. Virtus ETF Advisers LLC now owns 43,927 shares of the biotechnology company's stock valued at $325,000 after purchasing an additional 4,858 shares during the period. Hood River Capital Management LLC increased its stake in shares of Iovance Biotherapeutics by 10.4% in the fourth quarter. Hood River Capital Management LLC now owns 8,991,573 shares of the biotechnology company's stock valued at $66,538,000 after purchasing an additional 846,936 shares during the period. Finally, Long Focus Capital Management LLC raised its holdings in shares of Iovance Biotherapeutics by 13.2% during the fourth quarter. Long Focus Capital Management LLC now owns 5,132,000 shares of the biotechnology company's stock valued at $37,977,000 after buying an additional 600,000 shares during the last quarter. Institutional investors and hedge funds own 77.03% of the company's stock.

Iovance Biotherapeutics Stock Down 44.8 %

Shares of Iovance Biotherapeutics stock opened at $1.75 on Friday. Iovance Biotherapeutics, Inc. has a 12-month low of $1.65 and a 12-month high of $12.51. The firm has a market capitalization of $584.38 million, a PE ratio of -1.17 and a beta of 1.06. The stock's fifty day moving average is $3.36 and its 200-day moving average is $6.10.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.11). Iovance Biotherapeutics had a negative return on equity of 58.43% and a negative net margin of 451.25%. The company had revenue of $49.32 million for the quarter, compared to analyst estimates of $83.40 million. During the same quarter in the previous year, the firm posted ($0.42) EPS. Iovance Biotherapeutics's quarterly revenue was up 6795.1% on a year-over-year basis. Analysts expect that Iovance Biotherapeutics, Inc. will post -1.24 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. The Goldman Sachs Group decreased their price objective on Iovance Biotherapeutics from $18.00 to $16.00 and set a "buy" rating for the company in a report on Thursday, April 17th. JMP Securities restated a "market perform" rating on shares of Iovance Biotherapeutics in a research note on Friday. Barclays reduced their price objective on shares of Iovance Biotherapeutics from $22.00 to $5.00 and set an "overweight" rating for the company in a report on Monday, April 14th. Citizens Jmp cut shares of Iovance Biotherapeutics from an "outperform" rating to a "market perform" rating in a research note on Friday. Finally, Chardan Capital reduced their price target on shares of Iovance Biotherapeutics from $30.00 to $25.00 and set a "buy" rating for the company in a research note on Friday. One investment analyst has rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $16.33.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.